Overview

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Metformin
Vildagliptin